STIM - Neuronetics, Inc.
| Previous Close | 4.2900 |
| Open | 4.2800 |
| Bid | 4.1400 x 800 |
| Ask | 4.2200 x 1400 |
| Day's Range | 4.1573 - 4.3200 |
| 52 Week Range | 3.9600 - 18.4500 |
| Volume | 79,954 |
| Avg. Volume | 157,666 |
| Market Cap | 78.069M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 04, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- GlobeNewswire
Neuronetics Appoints Andrew Macan As Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced it has expanded its executive leadership team by adding Andrew Macan as its new Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary effective January 21, 2020. “A proven leader with more than 10 years of experience holding executive team roles at multiple corporations, Andrew is an exciting addition to the Neuronetics team,” said Chris Thatcher, President and Chief Executive Officer of Neuronetics.
- Simply Wall St.
If You Had Bought Neuronetics (NASDAQ:STIM) Stock A Year Ago, You'd Be Sitting On A 72% Loss, Today
Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...
- Insider Monkey
Neuronetics, Inc. (STIM) Is Burning These Hedge Funds
Is Neuronetics, Inc. (NASDAQ:STIM) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting […]
- GlobeNewswire
Neuronetics to Present at the 31st Annual Piper Jaffray Healthcare Conference
MALVERN, Pa., Nov. 25, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.
- GlobeNewswire
Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform
Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc. As a result of the transaction, Microchips is a wholly owned subsidiary of Daré. Microchips is developing an innovative, wireless, user-controlled drug delivery technology with potential utility across multiple therapeutic areas, including contraception. The application of this technology in developing a contraceptive product has been supported by the Gates Foundation in the form of approximately $17.9 million in grant funding to date.
- PR Newswire
Neuronetics® to Present New Depression Research at 15th Annual Neuroscience Education Institute Congress
Data confirms NeuroStar® Advanced Therapy is a proven and safe treatment option for those with medication-resistant depression MALVERN, Pa. , Nov. 7, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ: STIM), ...
- Zacks
Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of 9.76% and -0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Neuronetics Reports Third Quarter 2019 Financial and Operating Results
MALVERN, Pa., Nov. 05, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.
- GlobeNewswire
Neuronetics® Announces Appointment of Sheryl Conley to its Board of Directors
Neuronetics, Inc. (STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Sheryl Conley to its Board of Directors, effective immediately. Ms. Conley will be a member of the Audit Committee and after her appointment, the Neuronetics’ Board of Directors will have seven members. "We are thrilled to welcome Sheryl to the Board of Neuronetics as we look to advance our mission of improving the quality of life for patients who suffer from psychiatric disorders," said Chris Thatcher, President and CEO of Neuronetics.
- Simply Wall St.
How Much Are Neuronetics, Inc. (NASDAQ:STIM) Insiders Taking Off The Table?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- Zacks
Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for
Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Neuronetics® and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar® Advanced Therapy
MALVERN, Pa., Oct. 28, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced a partnership with Success TMS, a healthcare provider specializing in transcranial magnetic stimulation (TMS), a non-drug, non-invasive treatment for adult patients with Major Depressive Disorder (MDD). As part of a three-year agreement, Success TMS will offer Neuronetics' NeuroStar Advanced Therapy system as its preferred TMS device at 21 locations across six states.
- GlobeNewswire
Neuronetics to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 22, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.
- PR Newswire
Neuronetics CEO Chris Thatcher to Ring Nasdaq Closing Bell on October 22 in Honor of National Depression Awareness Month
MALVERN, Pa., Oct. 21, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will ring the Nasdaq Closing Bell on October 22 in honor of National Depression Awareness Month.
- PR Newswire
Neuronetics® Unveils Promising New Depression Research Data at Psych Congress
New findings confirm safety and efficacy of NeuroStar® Advanced Therapy, a non-drug depression treatment, setting the stage for future indications MALVERN, Pa. , Oct. 3, 2019 /PRNewswire/ -- Neuronetics, ...
- PR Newswire
Neuronetics® Honors Depression Conquerors For National Depression Awareness Month
MALVERN, Pa., Oct. 1, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is spotlighting the many faces and stories of depression to encourage an open dialogue and awareness of its non-drug treatment option in honor of National Depression Awareness Month. Sharing the stories of patient advocates who have been positively impacted by NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment, Neuronetics aims to educate on an innovative, safe and effective treatment option patients can turn to when antidepressant medications fail.
- PR Newswire
Neuronetics® Announces Greenbrook® TMS Installation Milestone for NeuroStar® Advanced Therapy System
MALVERN, Pa., Sept. 4, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Greenbrook TMS, a NeuroStar Advanced Therapy provider with 82 treatment centers across the U.S., has installed its 100th NeuroStar system. This is a significant milestone in the availability of NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment for patients. Greenbrook's Matthews, NC location now joins the growing number of practices offering NeuroStar TMS.
- Simply Wall St.
Is Neuronetics (NASDAQ:STIM) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- PR Newswire
Researchers at USU Unveil Neuronetics®-supported Clinical Research for PTSD and Traumatic Brain Injury at the Military Health System Research Symposium
MALVERN, Pa., Aug. 19, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced that researchers at the Uniformed Services University of the Health Sciences will present clinical data at the 2019 Military Health System Research Symposium (MHSRS) in Kissimmee, FL from August 19-22 from an investigator-initiated trial utilizing the Company's NeuroStar® Advanced Therapy TMS research system for PTSD and traumatic brain injury (TBI). In addition, they will present a case report of one patient treated and studied for Alzheimer's Disease.
Motley FoolNeuronetics, Inc. (STIM) Q2 2019 Earnings Call Transcript
STIM earnings call for the period ending June 30, 2019.
- Zacks
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 4.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Neuronetics Reports Second Quarter 2019 Financial and Operating Results
MALVERN, Pa., Aug. 06, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.
- PR Newswire
Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy
MALVERN, Pa., Aug. 1, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced that Kanagawa Psychiatric Center is treating the first patient in Japan using NeuroStar® Advanced Therapy under the newly approved reimbursement listing by Japan's Ministry of Health, Labour and Welfare (MHLW) and the Central Social Insurance Medical Council (Chuikyo).
- PR Newswire
Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients
MALVERN, Pa., July 29, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), the developer of NeuroStar® Advanced Therapy, the market leader in transcranial magnetic stimulation (TMS) for depression, announced today the launch of its TrakStar® Plus patient data management system. Based on feedback from physicians on the front lines of care who are actively treating patients with Major Depressive Disorder (MDD) with the NeuroStar device, these new features are focused on improving workflow, usability and access.
- GlobeNewswire
Neuronetics to Present at the 39th Annual Canaccord Genuity Growth Conference
MALVERN, Pa., July 25, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.
